Filing Analysis
Akari Therapeutics, Plc has filed an 8-K to announce its financial results for the first half of the fiscal year ending December 31, 2026. The filing serves as a formal announcement of the release of these earnings via press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: First half of the year ending December 31, 2026
- The filing includes a press release as Exhibit 99.1 containing financial results and other information.
- Signed by Kameel Farag, Interim Chief Financial Officer.
Akari Therapeutics held its Annual General Meeting on June 30, 2026. The meeting resulted in the non-election of director James Neal and several shareholder approvals regarding remuneration policies and share issuances.
🚩 Red Flags
- Director James Neal failed to be re-elected, indicating potential shareholder dissatisfaction or governance shifts.
- Approval of share issuances under Nasdaq Rule 5635(d) and (b) suggests significant dilution and the possibility of a change in control.
📋 Key Facts
- Annual General Meeting (AGM) held on June 30, 2026.
- Director James Neal failed to receive requisite shareholder approval and his service ended immediately.
- Dr. Ray Prudo appointed to the Audit Committee; Robert Bazemore appointed Chair of the Compensation Committee.
- Shareholders approved an ELOC Purchase Agreement involving Nasdaq Listing Rule 5635(d) compliance.
- Shareholders approved issuance of Series H, I, and J Warrants for up to 4,411,764 ADSs.
- Shareholders approved a potential 'change of control' via private placement under Nasdaq Listing Rule 5635(b).
- Ratification of BDO USA, P.C. as independent registered public accounting firm for the year ending Dec 31, 2026.
Akari Therapeutics, Plc completed the final closing of a private placement offering by combining its second and third tranches into a single consolidated closing on June 26, 2026. The company issued the remaining 980,395 American Depository Shares (ADSs) or prefunded warrants to investors.
🚩 Red Flags
- Use of 'unregistered' securities via private placement (PIPE) often indicates a need for immediate liquidity.
- The issuance involves warrants (Series H, I, and J), which can lead to significant future dilution for existing shareholders.
📋 Key Facts
- The Company completed a 'Combined Closing' on June 26, 2026, merging the previously scheduled second and third closings.
- Total offering size involves an aggregate of 1,470,588 unregistered ADSs (or prefunded warrants) plus Series H, I, and J warrants.
- The final tranche issued on June 26 consisted of 980,395 ADSs or prefunded warrants.
- Delivery of the Series Warrants is contingent upon shareholder approval at the annual general meeting scheduled for June 30, 2026.
Akari Therapeutics (AKTX) entered into a Securities Purchase Agreement on May 20, 2026 for a private placement offering of approximately $5.5 million gross proceeds. The offering involves 1,470,588 ADSs (or pre-funded warrants in lieu) at $3.74 per unit, accompanied by three series of warrants (Series H, I, and J), with funding structured across three tranches closing between May 27 and July 15, 2026. The placement agent (Paulson Investment Company) receives both a 2% cash fee and 117,647 ADSs (8% of total ADSs issued), and shareholder approval is required for warrant issuance.
🚩 Red Flags
- Small raise of only ~$5.5M gross ($5.375M net) signals limited financial runway and potential cash burn concern for a clinical-stage biotech
- Highly dilutive structure: each ADS unit carries THREE warrant series (H, I, J), each exercisable for one additional ADS — potential 4x dilution per unit if all warrants exercised
- Placement agent compensation is unusually high: 2% cash fee PLUS 8% of total ADSs issued (117,647 ADSs), effectively a dual-compensation structure
- Shareholder Approval is a contingent condition for warrant and placement agent ADS issuance — creates execution risk and potential deal uncertainty
- Use of proceeds for 'working capital and general corporate purposes' suggests no specific operational milestone, indicating ongoing cash need
- Offering price of $3.74/ADS may reflect significant discount to market, implying dilution to existing shareholders
- Three-tranche funding structure (not a single close) introduces future closing risk if market conditions deteriorate
- Multiple 8-K items filed simultaneously (Items 1.01, 3.02, 9.01)
📋 Key Facts
- Securities Purchase Agreement dated May 20, 2026 for a private placement offering
- 1,470,588 ADSs (each representing 80,000 ordinary shares) offered at $3.74 per Unit (ADS Unit Purchase Price)
- Pre-Funded Warrants offered at $3.739 per Unit (ADS Unit Purchase Price minus $0.001 exercise price)
- Gross proceeds expected to be approximately $5.5 million before deducting ~$125,000 in placement agent fees
- Three warrant series issued per unit: Series H, Series I, and Series J, each exercisable for one ADS at $3.74
- Funding structured in three tranches: ~May 27, 2026 (First Closing), June 15, 2026 (Second Closing), July 15, 2026 (Third Closing)
- Placement Agent (Paulson Investment Company, LLC) receives 2% cash fee AND 117,647 ADSs (8% of total ADSs issued)
- Shareholder Approval required before Series Warrants and Placement Agent ADSs can be issued
- Company must file Form S-3 (or S-1) registration statement within 30 days of Third Closing Date (July 15, 2026)
- Proceeds to be used for working capital and general corporate purposes
- Securities sold under Section 4(a)(2) exemption and Rule 506 of Regulation D to accredited investors only
- Filing signed by Abizer Gaslightwala, President and CEO, on May 22, 2026
Akari Therapeutics announced a 1-for-40 reverse split of its American Depositary Shares (ADSs) by changing the ratio from 1:2,000 to 1:80,000 ordinary shares. The change is scheduled to take effect on March 31, 2026, in an effort to regain or maintain compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Significant 1-for-40 reverse split ratio.
- Explicit mention of uncertainty regarding the ability to satisfy Nasdaq minimum bid price requirements even after the split.
📋 Key Facts
- The ADS ratio will change from one ADS representing 2,000 ordinary shares to one ADS representing 80,000 ordinary shares.
- The action results in a 1-for-40 reverse split of issued and outstanding ADSs.
- The effective date for the ratio change is approximately March 31, 2026.
- The change has no effect on the underlying ordinary shares, only the ADSs.
Akari Therapeutics held a Special General Meeting on March 2, 2026, where shareholders approved the exercisability of a massive volume of warrants issued in late 2025 and early 2026. These approvals, required by Nasdaq Listing Rule 5635, facilitate the potential issuance of over 26 million American Depositary Shares (ADSs) through Series G, Pre-Funded, and Note Exchange warrants.
🚩 Red Flags
- Extreme potential dilution: The warrants approved for exercise represent a significant percentage of the company's total equity (potentially exceeding 50% of current ADS equivalents).
- Reliance on Note Exchange Warrants suggests the company is converting debt to equity to manage its balance sheet.
- The use of Pre-Funded Warrants and Series G Warrants often indicates high-cost capital raising typical of distressed micro-cap entities.
📋 Key Facts
- Shareholders approved the exercisability of Series G Warrants for 10,043,774 ADSs and Placement Agent Warrants for 504,300 ADSs.
- Approved exercisability of Pre-Funded and Series G Warrants for approximately 5.1 million ADSs related to a December 2025 private placement.
- Approved exercisability of Pre-Funded and Note Exchange Warrants for approximately 28.3 million ADSs related to a December 2025 note exchange.
- Total ordinary shares entitled to vote at the meeting was 91,567,009,533 (equivalent to approximately 45.7 million ADSs).
- All resolutions passed with significant majorities, clearing the path for substantial equity dilution.
Akari Therapeutics announced a series of concurrent equity transactions, including a $5 million registered direct offering and private placement, alongside an exchange of $4 million in debt for equity/warrants. The total transaction provides approximately $9 million in combined cash proceeds and liability reduction.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 10 million ADSs and multiple tranches of warrants (Series G, Pre-Funded, Placement Agent, and Note Exchange Warrants).
- Heavy use of 'Pre-Funded Warrants' which allow insiders/investors to delay ADS issuance while maintaining economic exposure.
- Requirement for a Special Meeting to obtain shareholder approval for the warrant issuances.
- The debt exchange involves converting existing 20% original issue discount notes into equity instruments, indicating high cost of previous capital.
📋 Key Facts
- Registered Direct Offering: 10,043,774 ADSs + Series G Warrants at $0.3883 per ADS/Warrant combo.
- Private Placement (PIPE): Pre-Funded Warrants and Series G Warrants to directors/officers at ~$0.4041 per unit.
- Debt Exchange: Approximately $4 million of 2026 Notes exchanged for Pre-Funded Warrants and Note Exchange Warrants.
- Total combined value (cash + liability reduction): ~$9 million.
- Warrant terms: Series G Warrants have a 5-year term; exercise price is $0.3883 per ADS.
- Use of proceeds: R&D, working capital, and general corporate purposes.
Akari Therapeutics held a Special General Meeting on December 15, 2025, where shareholders approved several critical resolutions including the sub-division of ordinary shares and the issuance of deferred shares. The meeting also approved the exercisability of warrants from an October 2024 offering and granted directors broad authority to allot equity securities.
🚩 Red Flags
- Complex capital restructuring involving 'deferred shares' and sub-division of par value (often used to facilitate large equity issuances or manage voting rights).
- Broad authority granted to directors to allot equity securities for cash, potentially leading to future dilution.
📋 Key Facts
- Special General Meeting held on December 15, 2025.
- Shareholders approved the sub-division of USD 0.0001 ordinary shares into one Ordinary Share (USD 0.000000005) and 19,999 deferred shares.
- Approval granted for the exercisability of warrants issued in connection with an October 14, 2025, offering per Nasdaq Listing Rule 5635(d).
- Directors granted authority to allot equity securities for cash up to an aggregate nominal amount of USD 3,000 through June 30, 2030.
- Shareholders approved a share buyback contract involving the purchase of all Deferred Shares from shareholders.
Akari Therapeutics, Plc filed an 8-K to furnish an investor presentation intended for use at upcoming conferences and meetings. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The filing was made on December 8, 2025.
- The company prepared an investor presentation (Exhibit 99.1) to be used in conferences and meetings.
- Information provided under Item 7.01 is considered 'furnished' rather than 'filed', meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Akari Therapeutics, Plc received a notification from Nasdaq stating it is non-compliant with the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement
- Potential for reverse stock split (implied by mention of 'implementing a ratio change')
- Significant downward pressure on share price over 30 consecutive business days
📋 Key Facts
- Nasdaq notified the company on November 24, 2025, regarding a violation of Nasdaq Listing Rule 5550(a)(2).
- The deficiency is based on the ADS closing bid price being below $1.00 for 30 consecutive business days.
- The company has until May 25, 2026, to regain compliance by achieving a minimum $1.00 closing bid price for at least 10 consecutive business days.
- If compliance is not met by the deadline, the company may be eligible for an additional 180-day second compliance period if it meets other listing standards.
- The company is considering a ratio change of its ADSs to regain compliance.
Akari Therapeutics, Plc has appointed Kameel Farag as Interim Chief Financial Officer, effective October 22, 2025. Mr. Farag succeeds Torsten Hombeck and will serve until a permanent successor is appointed.
🚩 Red Flags
- Succession risk: The appointment is for an 'interim' role, indicating the company has not yet secured a permanent CFO.
- Contingent compensation: KDF Ventures receives success-based fees tied to future capital raises, which can create misaligned incentives during fundraising efforts.
📋 Key Facts
- Kameel Farag appointed as interim CFO on October 22, 2025.
- Interim term expected to run through February 16, 2026, with month-to-month extensions possible.
- Compensation includes a monthly cash fee of $18,000 and $12,000 in RSUs through year-end 2025; fees increase to $27,000 cash and $13,000 RSUs in early 2026.
- KDF Ventures LLC (associated with Farag) is entitled to compensation based on a percentage of gross proceeds from future capital raises.
- Mr. Farag previously held executive roles at Aspen Neuroscience, Ionis Pharmaceuticals, and Amgen Inc.
Akari Therapeutics entered into a securities purchase agreement for a registered direct offering of 3,125,000 American Depositary Shares (ADSs) and accompanying Series E and F warrants. The offering aims to raise approximately $2.5 million in gross proceeds to fund working capital and R&D activities.
🚩 Red Flags
- Significant dilution: The issuance of warrants (Series E and F) represents a substantial potential increase in share count.
- Warrant overhang: Warrants are issued at $0.98, which is higher than the current offering price of $0.80, but their existence creates significant future dilution.
- Small capital raise: The $2.5 million gross proceeds is relatively small for a biotech company, suggesting limited runway extension.
- Required shareholder approval: The necessity of a Special Meeting to approve warrant exercises indicates potential governance/structural hurdles.
📋 Key Facts
- Offering size: 3,125,000 ADSs (each representing 2,000 ordinary shares).
- Combined purchase price per ADS and accompanying Warrants: $0.80.
- Expected gross proceeds: ~$2.5 million.
- Series E Warrants: 3,125,000 warrants with an exercise price of $0.98 and a 5-year term.
- Series F Warrants: 3,125,000 warrants with an exercise price of $0.98 and a 30-month term.
- Placement Agent: Ladenburg Thalmann & Co. Inc., receiving 7.2% placement fee and 0.5% management fee.
- The company must seek shareholder approval for the issuance of ADSs issuable upon warrant exercise via a Special Meeting within 60 days of closing.
Akari Therapeutics, Plc announced a $2.5 million registered direct offering on October 15, 2025. The filing serves to furnish the press release announcing the capital raise under Item 7.01.
🚩 Red Flags
- Small offering size ($2.5M) relative to typical micro-cap market caps may indicate immediate need for working capital.
📋 Key Facts
- Company announced a $2.5 million Registered Direct Offering.
- The announcement was made via press release on October 15, 2025.
- Filing is being furnished pursuant to Item 7.01 (Regulation FD Disclosure).
Akari Therapeutics, Plc has closed the final tranche of its August 2025 Notes Offering. This brings the total aggregate principal amount issued under this offering to approximately $3.8 million.
🚩 Red Flags
- High-interest financing: The notes include a significant 20% original issuance discount, indicating expensive capital for the company.
📋 Key Facts
- Final tranche closed on September 26, 2025.
- The final tranche involved issuing $312,500 in aggregate principal for an aggregate purchase price of $250,000.
- Total aggregate principal amount issued via the August 2025 Notes Offering is approximately $3.8 million.
- Notes carry a 20% original issuance discount.
Akari Therapeutics amended existing convertible notes and warrants to extend maturities and significantly reduce conversion prices, while also reporting the closing of a second tranche of a $3.8 million debt offering. The filing also highlights positive preclinical data for its PH1 ADC payload in treating prostate cancer.
🚩 Red Flags
- Significant dilution risk due to massive increase in number of shares issuable via warrants (684.8M ordinary shares).
- Aggressive downward adjustment of conversion prices/exercise prices (from $2.04 to $0.81) suggests distressed financing terms.
- High-cost debt: August 2025 Notes carry a 20% original issuance discount.
- Multiple rounds of dilutive financing and debt amendments within a short period.
📋 Key Facts
- Amended April 2023 Notes: Maturity extended to August 31, 2026; conversion price reduced from $2.04 to $0.81 per ADS.
- Amended April 2023 Warrants: Expiration extended to August 31, 2030; exercise price reduced from $2.04 to $0.81 per ADS; total ADSs issuable increased to 342,420 (684,840,000 Ordinary Shares).
- August 2025 Notes Offering: Second tranche closed on Sept 24, 2025, issuing $625,000 in principal for a $500,000 purchase price (20% original issuance discount).
- Total August 2025 Notes issued to date: $3.5 million of an aggregate $3.8 million.
- Preclinical data released for PH1 ADC payload showing suppression of AR-V7 receptor in prostate cancer models.
Akari Therapeutics entered into a $25 million Equity Line of Credit (ELOC) with White Lion Capital, LLC to issue new ordinary shares. Additionally, the company announced the resignation of its CFO, Torsten Hombeck, effective October 10, 2025.
🚩 Red Flags
- Significant dilution risk due to the $25M ELOC and potential issuance of up to 13 billion ordinary shares.
- Pricing mechanisms for the ELOC (e.g., 97% of VWAP or lowest traded price) indicate highly dilutive terms for existing shareholders.
- Unexpected departure of the Chief Financial Officer (CFO), though stated as being for personal reasons and not due to disagreement.
- Multiple material events in a single filing (ELOC + CFO Departure).
📋 Key Facts
- Entered into an Ordinary Share Purchase Agreement with White Lion Capital, LLC on August 29, 2025.
- The ELOC allows for the sale of up to $25,000,000 in newly issued Ordinary Shares.
- Purchase prices include options for Rapid Purchase (at a discount/lowest price) and VWAP-based pricing at 97-98% of market value.
- The agreement includes an 'Exchange Cap' of 13,039,369,358 Ordinary Shares (19.99% of outstanding shares).
- CFO Torsten Hombeck resigned on August 28, 2025, effective October 10, 2025; will consult until November 30, 2025.
- The company must file a registration statement (Form S-1) within 30 days to register the resale of these shares.
Akari Therapeutics completed the first tranche of a private placement offering of unsecured promissory notes with a 20% original issuance discount. The transaction involved significant debt restructuring and warrant extensions for existing investors.
🚩 Red Flags
- High-cost financing: 20% original issuance discount on unsecured promissory notes is highly dilutive/expensive.
- Related-party transaction: The Company's Chairman, Dr. Hoyoung Huh, participated in the offering and used a debt cancellation of $837,433 from a subsidiary (Peak Bio Inc.) to satisfy part of his purchase price.
- Debt restructuring via equity-linked instruments: Extension of warrants by 48 months suggests significant dilution pressure for existing shareholders.
- High advisory fees: A 5% cash advisory fee was paid to Paulson Investment Company on gross proceeds.
📋 Key Facts
- Completed first tranche closings on August 15 and August 18, 2025.
- Issued Notes with an aggregate purchase price of $2,261,000 and principal amount of $2,826,250.
- Notes carry a 20% original issuance discount and have a 12-month maturity from the closing dates.
- The Company extended the expiration date of Series A Warrants by 48 months for certain Note Investors.
- Chairman Dr. Hoyoung Huh participated in the offering, purchasing a $1,250,000 note for $1,000,000 via cash and debt cancellation.
Akari Therapeutics, Plc filed an 8-K to provide an updated corporate investor presentation. This is a routine disclosure used to communicate company updates and strategy to the market.
📋 Key Facts
- Company released an updated investor presentation on August 19, 2025.
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The company intends to use the updated presentation in various upcoming meetings.
Akari Therapeutics held its 2025 Annual General Meeting on June 30, 2025, where shareholders approved a significant increase in the number of shares available under the 2023 Equity Incentive Plan. The company also successfully passed resolutions regarding director re-elections and auditor appointments.
🚩 Red Flags
- Significant dilution potential: The approval of 4.2% of the current issued share capital for director stock options and a massive increase in the equity incentive pool indicates substantial future dilution for existing shareholders.
- High volume of ordinary shares involved in voting/incentives (billions of shares) suggests complex capital structure typical of micro-cap biotech firms.
📋 Key Facts
- Shareholders approved an increase in the 2023 Equity Incentive Plan by 11,026,000,000 ordinary shares (equivalent to 5,513,000 ADSs).
- The total number of shares available under the 2023 Plan increased to 19,806,000,000 ordinary shares.
- Shareholders approved a one-time grant of stock option awards over 225,000 ADSs (450,000,000 ordinary shares) to certain directors, representing approximately 4.2% of the company's current issued share capital.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
- Directors Hoyoung Huh, Robert Bazemore, James Neal, Sandip I. Patel, Samir R. Patel, and Abizer Gaslightwala were re-elected or confirmed.
Akari Therapeutics, Plc filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a vehicle to furnish the quarterly press release via Exhibit 99.1.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results and other information.
- The company is listed on the Nasdaq Capital Market under ticker AKTX.
Akari Therapeutics, Plc issued an 8-K to furnish its financial results for the second half and full year ended December 31, 2024. The filing serves as a formal announcement of earnings/financial performance via a press release.
📋 Key Facts
- Report date: April 16, 2025
- Reporting period: Second half and full year ended December 31, 2024
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
Akari Therapeutics announced a leadership transition involving the appointment of Abizer Gaslightwala as President and CEO, effective around April 21, 2025. The current CEO, Dr. Samir R. Patel, will step down from his executive role on April 14, 2025, but will remain on the Board of Directors.
🚩 Red Flags
- Performance-based equity triggers are tied to specific capital raising ($15M) or licensing ($10M) milestones by year-end 2025, indicating potential liquidity/commercial pressure.
- CEO departure terms for Dr. Patel are currently undisclosed and still being finalized.
📋 Key Facts
- Abizer Gaslightwala appointed President and CEO; effective date approx. April 21, 2025.
- Mr. Gaslightwala's annual base salary is $475,000 with a target cash bonus of 50%.
- Compensation includes 1,100,000 ADS stock options and 600,000 ADS performance options subject to Board approval.
- Performance options vest based on achieving a $15M qualified financing or a $10M antibody drug conjugate license transaction by Dec 31, 2025.
- Dr. Samir R. Patel stepping down as CEO effective April 14, 2025; will remain on the Board.
- Mr. Gaslightwala has a background at Jazz Pharmaceuticals, Amgen, and Pfizer.
Akari Therapeutics entered into a private placement agreement to issue 6,637,626 American Depository Shares (ADSs) or pre-funded warrants to investors, including the company's Chairman and CEO. The offering is expected to raise approximately $7.1 million in gross proceeds for working capital.
🚩 Red Flags
- Related-party transaction: The Chairman, CEO, and all board members are participating in the offering.
- Note Termination: Conversion/termination of a $1 million convertible note held by the Chairman is part of the deal structure.
- Dilution risk: Issuance of significant amounts of unregistered ADSs and multiple series of warrants (Series A and B) will lead to substantial dilution for existing shareholders.
- Warrant overhang: The inclusion of Series A and B warrants creates potential future dilution.
📋 Key Facts
- Total aggregate issuance: 6,637,626 unregistered American Depository Shares (ADSs) or pre-funded warrants.
- Expected gross proceeds: Approximately $7.1 million (including a $1 million note termination).
- Pricing structure: Tiered pricing based on investment amount ($0.87 base + tier-specific premium).
- Warrant terms: Series A and B warrants included with exercise prices of $0.87 per ADS.
- Note Termination: Chairman Dr. Hoyoung Huh is terminating a $1 million convertible note in exchange for $1 million in Units.
- Placement Agent: Paulson Investment Company, LLC (7% cash fee; 3% shares/ADSs fee).
- Registration obligation: Company must file Form S-3 within 60 days of closing to register resale.
Akari Therapeutics, Plc updated its corporate slide presentation via an Exhibit 99.1 filing under Item 7.01 (Regulation FD Disclosure). The update is intended for use in various upcoming meetings and does not constitute a material change to previously filed financial data.
📋 Key Facts
- The company updated its corporate presentation on January 13, 2025.
- The updated information is attached as Exhibit 99.1.
- The filing was made under Item 7.01 (Regulation FD Disclosure) to provide non-public/updated information for meetings.
Akari Therapeutics announced several leadership changes effective December 16, 2024, including the permanent appointment of Dr. Samir R. Patel as CEO and the addition of Abizer Gaslightwala to the Board. Additionally, director Michael Grissinger submitted his resignation.
🚩 Red Flags
- Director resignation (though explicitly stated as non-dispute related).
📋 Key Facts
- Dr. Samir R. Patel appointed as Chief Executive Officer effective December 16, 2024 (previously interim CEO since May 2024).
- Abizer Gaslightwala appointed to the Board of Directors effective December 16, 2024; deemed independent by Nasdaq rules.
- Gaslightwala brings significant industry experience from Jazz Pharmaceuticals, Amgen, and Pfizer.
- Michael Grissinger resigned from the Board effective December 16, 2024; resignation was not due to any disagreement with company operations or practices.
Akari Therapeutics, Plc announced the appointment of Torsten Hombeck as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck returns to the company after previously serving as CFO from October 2019 until June 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Torsten Hombeck appointed as CFO, Principal Financial Officer, and Principal Accounting Officer.
- Effective date of appointment: December 16, 2024.
- Annual base salary for Dr. Hombeck is $300,000 with a target bonus of up to 100%.
- Dr. Hombeck previously served as the company's CFO from October 2019 until June 2024.
Akari Therapeutics announced the termination of Interim CFO Wendy DiCicco on December 6, 2024. Consequently, interim CEO Samir Patel has been appointed to serve as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.
🚩 Red Flags
- Sudden departure of the Interim CFO/PFO/PAO creates temporary leadership gaps in financial oversight.
- The company is relying on its interim CEO to perform dual roles (CEO and PFO), which may strain executive bandwidth during a transition.
📋 Key Facts
- Wendy DiCicco's consulting agreement was terminated effective December 6, 2024; she is no longer serving as Interim CFO, PFO, or PAO.
- Samir Patel (Interim CEO) appointed as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.
- The Board has initiated a search for a permanent Chief Financial Officer.
- Severance terms for Ms. DiCicco are currently being finalized and have not yet been disclosed.
Akari Therapeutics completed a strategic merger with Peak Bio, Inc., making Peak Bio a wholly owned subsidiary. Simultaneously, the company entered into a $3.2 million private placement of ADS and warrants involving insiders.
🚩 Red Flags
- Related-party transaction: Insiders (Chairman and Interim CEO) participated in the private placement at a premium price.
- Delisting risk history: Company previously received a Nasdaq delisting notice for failing to meet the $2.5M stockholders' equity requirement.
- Dilution: Issuance of significant new ADS and warrants via private placement and merger.
📋 Key Facts
- Completed merger with Peak Bio, Inc. on November 14, 2024; Akari ADSs issued to Peak shareholders at an exchange ratio of 0.2935.
- Entered into a $3.2 million private placement of 1,713,402 unregistered ADS and Series D Warrants.
- Private placement includes insiders Dr. Ray Prudo (Chairman) and Dr. Samir R. Patel (Interim CEO/Director).
- Insiders purchased ADS at a premium ($2.385 per unit vs $1.70 for other investors).
- Warrants have a 3-year term with an exercise price of $2.26 per ADS.
- Company intends to file Form S-3 within 30 days of the private placement closing to register resale.
Akari Therapeutics held a general meeting where shareholders approved all six proposals related to its proposed merger with Peak Bio, Inc. The approval includes authorizations for share allotments and issuances necessary to execute the transaction.
🚩 Red Flags
- Significant potential dilution for existing shareholders due to the massive increase in equity incentive plan and merger-related share issuances.
📋 Key Facts
- Shareholders approved the Merger Allotment Proposal (up to $14,444,680 in ordinary shares).
- Approved the Share Issuance Proposal for Nasdaq compliance regarding the merger.
- Approved the appointment of Hoyoung Huh, M.D., Ph.D. as non-executive chairman effective upon merger completion.
- Approved a General Allotment Proposal up to $5,546,667 through November 2029.
- Approved an expansion of the 2023 Equity Incentive Plan by 7.8 billion ordinary shares.
- Quorum was met with approximately 60.1% of entitled shares represented (14,591,339,889 shares).
- All six proposals passed via poll.
Akari Therapeutics received a delisting determination letter from Nasdaq after failing to meet the $2,500,000 stockholders' equity requirement. The company intends to request a hearing before a Nasdaq Hearing Panel to stay any suspension of trading.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum stockholders' equity requirement
- Expiration of previous compliance extension (Sept 30, 2024)
- Imminent threat of trading suspension
📋 Key Facts
- Nasdaq issued a Delisting Determination Letter on October 1, 2024.
- The company failed to comply with the Stockholders’ Equity Requirement ($2.5M minimum).
- An extension was previously granted until September 30, 2024, which has now expired without compliance.
- Trading suspension will occur if a hearing request is not filed by October 8, 2024.
- The company expects to regain compliance via its pending merger with Peak Bio, Inc.
Akari Therapeutics announced the appointment of Robert Bazemore to its Board and an amendment to Interim CEO Dr. Samir Patel's compensation structure. Additionally, the company provided updates on its pending merger with Peak Bio, Inc., noting the filing of a Form S-4 registration statement.
🚩 Red Flags
- Complexity of CEO compensation structure involving NQSOs tied to monthly closing prices may lead to dilution or volatility.
- The merger is subject to multiple high-bar conditions, including a required PIPE investment and specific net cash requirements for Peak Bio.
📋 Key Facts
- Board expansion: Robert Bazemore appointed as a new independent director effective September 17, 2024.
- CEO Compensation Amendment: Dr. Samir Patel's monthly $50,000 compensation will now be paid in non-qualified stock options (NQSOs) instead of fully vested ordinary shares; the number of ADS units is calculated as $50,000 divided by the closing price on the last day of each month.
- Merger Update: Akari filed a Registration Statement on Form S-4 on September 13, 2024, in connection with its merger with Peak Bio, Inc.
- Merger Conditions: Closing is contingent upon shareholder approval, regulatory clearance, and a PIPE investment resulting in at least $10 million net proceeds to Akari.
The filing contains extensive data regarding complex financial instruments, including multiple convertible notes and warrants involving related parties, directors, and founders. The presence of significant derivative liabilities and conversion features suggests a highly leveraged capital structure with potential dilution risks.
🚩 Red Flags
- High complexity in capital structure with multiple layers of convertible debt (April 2023, Dec 2023, May 2024).
- Significant related-party transactions involving convertible notes and director/founder loans.
- Extensive use of Level 3 fair value inputs for derivative liabilities, indicating high valuation uncertainty.
- Potential for massive dilution due to the volume of warrants and conversion features associated with various debt tranches.
📋 Key Facts
- Multiple convertible note series identified: November 2022, April 2023, December 2023, and May 2024.
- Significant use of 'Related Party' transactions involving the April 2023 Convertible Notes and December 2023 Convertible Notes.
- Existence of various derivative liabilities including WhiteLion Derivative Liability and Key Company Stockholder Forward Liabilities.
- Extensive warrant activity: Private Placement Warrants, Pipe Warrants, and Founder/Director Warrants.
- Presence of 'Employee and Director Loans' as a line item in the financial data.
Akari Therapeutics, Plc filed an amendment to its 8-K to disclose the specific terms of a separation agreement with former President and CEO Rachelle Jacques. The agreement includes a lump sum payment and significant adjustments to her restricted stock units (RSUs).
🚩 Red Flags
- Significant equity adjustments (forfeiture/vesting) involving hundreds of millions of ordinary shares.
- The separation payment is tied to an 'anticipated merger with Peak Bio, Inc.', indicating ongoing M&A activity and potential execution risk.
📋 Key Facts
- Rachelle Jacques stepped down as President and CEO effective May 1, 2024.
- A separation agreement was entered into on August 19, 2024.
- The company will make a one-time lump sum payment of $450,000 to Ms. Jacques.
- Payment is due upon the earlier of: (a) closing of an anticipated merger with Peak Bio, Inc., or (b) December 2, 2024.
- The agreement involves the vesting of 276,000,000 ordinary shares in RSUs and the forfeiture of 482,250,000 ordinary shares in RSUs.
Akari Therapeutics, Plc announced its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release via press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 19, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and other information.
Akari Therapeutics held its Adjourned Annual General Meeting on June 28, 2024, after failing to reach a quorum at the initial meeting on June 27. All submitted matters were approved, including the election of directors and the ratification of auditors.
🚩 Red Flags
- Initial failure to establish a quorum at the first AGM meeting suggests potential shareholder engagement or participation issues.
📋 Key Facts
- The original AGM on June 27, 2024, failed to establish a quorum.
- The Adjourned AGM was held on June 28, 2024, where all matters were approved.
- Ratification of BDO USA, P.C. as independent registered public accounting firm for the year ending Dec 31, 2024.
- Ratification of Haysmacintyre LLP as statutory auditors.
- Re-election of directors: Donald Williams, Michael Grissinger, Mohamed Wa’El Ahmed Hashad, Samir Patel, and Raymond Prudo-Chlebosz.
- Shareholders approved an annual frequency for advisory votes on executive compensation (NEO Say-on-Pay).
- Total ordinary shares entitled to vote: 15,847,391,523.
Akari Therapeutics, Plc has formalized an Interim CEO Agreement with Dr. Samir R. Patel, effective May 1, 2024. The agreement is notable for its strictly equity-based compensation structure designed to align the interim leader's interests with shareholders.
🚩 Red Flags
- Interim leadership status often suggests a period of transition or instability within the executive suite.
- The use of an 'at-will' independent contractor for the CEO role indicates high volatility in leadership stability.
📋 Key Facts
- Dr. Samir R. Patel appointed as Interim President and Chief Executive Officer effective May 1, 2024.
- Compensation is entirely equity-based: $50,000 per month paid in fully vested ordinary shares based on the Nasdaq closing price of the last day of each month.
- The agreement includes no annual bonus provision, no employee benefits (health, retirement, etc.), and no severance entitlements.
- Dr. Patel serves as an independent contractor on an at-will basis; the Company may terminate the agreement immediately for any reason.
Akari Therapeutics entered into a private placement agreement to issue 4,029,754 American Depository Shares (ADSs) and warrants at $1.885 per unit. The offering involves significant participation from the company's Chairman and Interim CEO.
🚩 Red Flags
- Related-party transaction: The offering includes participation from the Company's Chairman (Dr. Ray Prudo) and Interim CEO/Director (Samir R. Patel).
- Potential dilution: Issuance of over 4 million ADSs and corresponding warrants will significantly dilute existing shareholders.
- Warrant overhang: Significant number of warrants issued to investors and placement agents could lead to future downward pressure on stock price upon exercise.
📋 Key Facts
- Private placement of 4,029,754 unregistered ADSs and Series C Warrants.
- Unit price: $1.885 per ADS and Warrant.
- Warrant term: 3 years with cashless exercise provisions.
- Placement agent (Paulson Investment Company, LLC) received an 8% cash fee; insiders paid a 2% fee.
- Company committed to filing a Form S-3 registration statement by June 28, 2024, for the resale of these securities.
Akari Therapeutics, Plc issued an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a formal vehicle to furnish the quarterly earnings press release.
📋 Key Facts
- The company announced financial results for the fiscal quarter ending March 31, 2024.
- The announcement was made via a press release dated May 16, 2024.
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition).
Akari Therapeutics is implementing a massive restructuring plan involving a 67% reduction in its total workforce following the suspension of its HSCT-TMA program. The company also reported the resignation of a Board member.
🚩 Red Flags
- Massive workforce reduction (67%) indicates significant distress or a major pivot in business model.
- Suspension of a core program (HSCT-TMA) suggests failure or deprioritization of a key clinical asset.
- Multiple 8-K items reported in one filing (Restructuring + Director Departure).
- Significant cash outflow ($3.1M-$3.2M) for severance during a period of strategic contraction.
📋 Key Facts
- Implementation of a reduction-in-force (RIF) affecting approximately 67% of the total workforce as of May 1, 2024.
- The RIF includes the elimination of certain senior management positions.
- Restructuring is driven by the suspension of the HSCT-TMA program and a shift in strategic prioritization.
- Estimated restructuring costs are $3.1 million to $3.2 million, including $1.6 million in non-cash equity vesting expenses.
- Costs are expected to be paid through Q4 2024.
- Director Rachelle Jacques resigned from the Board effective May 7, 2024; no disagreement was noted.
Akari Therapeutics experienced significant leadership turnover with the departure of its CEO (Rachelle Jacques) and COO (Melissa Bradford-Klug), effective May 1, 2024. Dr. Samir R. Patel has been appointed as Interim CEO to lead the company through a planned merger with Peak Bio Inc.
🚩 Red Flags
- Simultaneous departure of both CEO and COO within a single week.
- Termination of COO 'without cause' often signals internal friction or restructuring.
- Significant related-party transaction: Interim CFO Wendy DiCicco received a 1% RSU grant and a performance bonus tied to the upcoming merger.
📋 Key Facts
- CEO Rachelle Jacques stepped down effective May 1, 2024; separation terms are currently undisclosed.
- COO Melissa Bradford-Klug was terminated without cause effective May 1, 2024.
- Dr. Samir R. Patel appointed Interim President and CEO effective May 1, 2024, with monthly compensation of $50,000 in RSUs.
- The company entered into an amendment to the consulting agreement for interim CFO Wendy DiCicco, including a 1% RSU grant vesting in one year and a 10% transaction bonus upon the Peak Bio Inc. merger.
- Company completed a joint pipeline assessment following the definitive agreement to merge with Peak Bio Inc.
Akari Therapeutics, Plc received a notice from Nasdaq stating it is no longer in compliance with the minimum stockholders' equity requirement. The company reported a stockholders' deficit of $229,000 as of December 31, 2023.
🚩 Red Flags
- Delisting notice regarding minimum stockholders' equity requirement
- Negative stockholders' equity (deficit of $229,000)
- Risk of delisting if a compliance plan is not accepted or successfully executed
📋 Key Facts
- Nasdaq notified the company on April 5, 2024, regarding non-compliance with Nasdaq Listing Rule 5550(b)(1).
- The company reported a stockholders' deficit of $229,000 as of December 31, 2023.
- The minimum stockholders' equity requirement for continued listing is $2,500,000.
- The company must submit a compliance plan by May 20, 2024.
- If a plan is accepted, the company may receive an extension to regain compliance through October 2, 2024.
Akari Therapeutics, Plc issued an 8-K to furnish its financial results for the second half and full year ended December 31, 2023. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Reporting period: Second half and full year ended December 31, 2023.
- Filing date: April 1, 2024.
- The filing includes Exhibit 99.1 containing the press release with financial results.
Akari Therapeutics entered into a private placement agreement to issue approximately $1.615 million in American Depository Shares (ADSs) to existing investors at a significant discount to market price. The offering includes a 10% cash fee and warrants issued to Paulson Investment Company, LLC.
🚩 Red Flags
- Significant discount to market price (70% of current/recent trading price) indicates potential distress or urgent need for capital.
- High transaction costs: 10% cash fee plus warrants issued to a single investor (Paulson).
- Dilutive financing structure involving unregistered securities and upcoming S-3 registration.
📋 Key Facts
- Private placement of ~$1,615,000 in unregistered American Depository Shares (ADSs).
- Pricing is set at the lower of: (i) 70% of the March 4, 2024 closing price or (ii) 70% of the 15-day VWAP following the merger announcement, subject to a floor of $1.12 per ADS.
- Paulson Investment Company, LLC will receive a cash fee equal to 10% of the aggregate purchase price.
- Paulson will also receive warrants to purchase 10% of the total number of ADSs placed at an exercise price of 125% of the offering price.
- The company plans to file a Form S-3 registration statement by March 31, 2024, for the resale of these ADS's.
Akari Therapeutics, Plc entered into a definitive merger agreement to acquire Peak Bio, Inc. via a reverse takeover structure. The transaction involves the issuance of Akari ADSs to Peak Bio stockholders and is contingent upon several conditions including shareholder approval and a simultaneous PIPE investment.
🚩 Red Flags
- The merger is contingent upon a PIPE investment of at least $10M, indicating a need for immediate capital infusion.
- Transaction requires Akari shareholders to authorize the allotment of all new shares issued in the merger.
📋 Key Facts
- Entered into an Agreement and Plan of Merger with Peak Bio, Inc. on March 4, 2024.
- Peak Bio will become a wholly-owned subsidiary of Akari following the merger.
- The exchange ratio is expected to result in approximately 50% of the outstanding shares of Akari ADSs being issued to Peak Bio stockholders.
- The transaction is subject to a PIPE investment resulting in net proceeds to Akari of at least $10,000,000.
- Closing is contingent upon Peak Bio's net cash being greater than negative $13,500,000.
- Termination fee is set at $300,000 plus reimbursement of expenses up to $1.5 million.
Akari Therapeutics entered into a private placement agreement with existing investors, including the Company's Chairman and a Director, to issue 947,868 American Depository Shares (ADSs) at $2.11 per ADS. The company also announced its transition from a foreign private issuer to a domestic issuer effective January 1, 2024.
🚩 Red Flags
- Related-party transaction: The securities were sold directly to the Company's Chairman and a Director.
- Potential dilution: The issuance of nearly 950k ADSs (each representing 2,000 ordinary shares) represents significant potential dilution for existing shareholders upon S-3 registration.
- Increased regulatory burden: Transitioning to domestic issuer status increases compliance costs and reporting requirements.
📋 Key Facts
- Private placement of 947,868 unregistered American Depository Shares (ADSs) at $2.11 per ADS.
- The offering was made to existing investors, specifically Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D.
- Placement agent Paulson Investment Company, LLC received a 5% cash fee plus a $60,000 expense allowance.
- Company committed to filing an S-3 registration statement by March 31, 2024, for the resale of these ADSs.
- Effective January 1, 2024, Akari transitioned from a foreign private issuer to a U.S. domestic issuer.